PEGBIO CO-B (ASX: 02565) has announced that its internally developed circular RNA-encoded GLP-1 analog, CR059, has had its research findings accepted for presentation at the 62nd European Association for the Study of Diabetes Annual Meeting 2026 (EASD 2026). The research has been selected for an oral discussion session.
This acceptance follows the prior selection of CR059-related research for the Late-Breaking Abstract session at the American Diabetes Association Scientific Sessions. The consecutive recognition by these two premier global academic conferences in diabetes and metabolic diseases underscores the high level of attention and validation CR059 and the company's circular RNA technology platform have garnered.
The accepted study is titled "Single-dose CR059, a circular RNA-encoded GLP-1 analogue, enables sustained exposure and prolonged body weight reduction in non-human primates." CR059 is a next-generation GLP-1 analog developed on the company's proprietary circular RNA platform. It is designed to enable sustained in vivo expression of the GLP-1 analog via circular RNA encoding, aiming for continuous drug exposure and long-term metabolic regulation.
This project represents a novel therapeutic approach, distinct from traditional peptide-based GLP-1 receptor agonists that rely on extending drug half-life. Instead, it explores a new drug modality for long-term treatment of metabolic diseases through the mechanism of circular RNA-encoded expression, positioning it as an innovative therapeutic technology with frontier attributes, platform scalability, and potential for generational advancement.
The company believes the core innovative value of CR059 lies in its potential to move beyond the current weekly dosing regimen predominant in existing GLP-1 drugs. It aims to extend towards ultra-long-acting treatment with dosing intervals of a month or longer, potentially even quarterly. Successful clinical translation of this technological pathway could significantly reduce the long-term dosing burden for patients with chronic metabolic diseases, improve treatment adherence and long-term management efficiency, and offer a next-generation solution for obesity, type 2 diabetes, and related metabolic disorders that is distinct from current peptide-based drugs.
The EASD Annual Meeting is one of the most influential international academic conferences in the field of diabetes and metabolic diseases, forming, alongside the ADA meeting, the most important global platform for academic exchange in this area. Selection for an oral discussion session is a significant presentation format granted by the EASD scientific committee, typically reserved for research with high innovation, scientific value, and field relevance. The opportunity for CR059 to be presented in this manner demonstrates the project's strong international academic appeal regarding its novel drug modality, ultra-long-acting mechanism, and potential clinical application prospects.
PEGBIO CO-B views this acceptance for an oral presentation at EASD 2026, following the ADA Late-Breaking Abstract selection, as another important milestone in the company's global efforts in next-generation innovative metabolic disease drug development. This progress not only highlights the frontier nature and differentiated potential of the CR059 project itself but also further validates the application value and international competitive potential of the company's circular RNA technology platform for long-acting and ultra-long-acting metabolic disease treatments.
The company already has an approved long-acting GLP-1 receptor agonist, Vipenotide Injection, and continues to develop next-generation innovative metabolic disease therapies represented by CR059. The continued advancement of CR059 supports the company's evolution from an innovator with an approved GLP-1 drug to a metabolic disease innovation enterprise with a platform R&D capability and global academic influence, covering weekly, monthly-plus, and potentially quarterly ultra-long-acting GLP-1 technological routes.
The company believes these developments will further enhance its technological distinctiveness, academic reputation, pipeline value, and potential for international collaboration within the global metabolic disease drug R&D landscape.
Comments